Abstract
A small pre-treatment 'priming' dose of cyclophosphamide will reduce gut damage due to high dose i.v. melphalan in mice and sheep but efforts to demonstrate this effect in man have been hampered by difficulty in the measurement of gut damage. We have evaluated the 51CR EDTA absorption test, a new method for measuring intestinal permeability, as a means of assessing damage due to high dose melphalan. The test was reliable, with a narrow normal range, easy to use and well tolerated. It detected an increase in intestinal permeability after high dose melphalan with a maximum occurring between 9 and 15 days after treatment and subsequently returning to normal. It was shown in 19 patients that a pre-treatment dose of cyclophosphamide was capable of significantly reducing the abnormalities in intestinal permeability which resulted from high dose melphalan.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Selby, P., Lopes, N., Mundy, J. et al. Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy. Br J Cancer 55, 531–533 (1987). https://doi.org/10.1038/bjc.1987.108
Issue Date:
DOI: https://doi.org/10.1038/bjc.1987.108
This article is cited by
-
Gut protection by cyclophosphamide ?priming? in patients receiving high-dose melphalan ? effect of drug scheduling
Cancer Chemotherapy and Pharmacology (1992)